OBJECTIVE: This phase I study aimed to determine the maximal tolerated dose of cisplatin administered every 2 weeks with infusional 5-fluorouracil (5FU) and concurrent radiation therapy (RT) in patients after complete resection of gastric adenocarcinoma. METHODS: Patients with resected stage IB to IV (M0) gastric adenocarcinoma were treated with 12 weeks of infusional 5FU (200 mg/m(2) daily) and with RT (45 Gy in 25 fractions starting on day 16). Cisplatin was administered in escalating doses (0, 20, 30, and 40 mg/m(2)) in weeks 1, 3, 5, and 7. In the final cohort, patients received an additional dose of cisplatin (40 mg/m(2)) in week 9. RESULTS: Among the 34 patients [median age: 56 years (range: 31-77 years)] who were assessable for toxicity, 5 experienced dose-limiting toxicities: 1 sepsis (cohort 1), 1 fatigue (cohort 2), 3 upper gastrointestinal toxicity (1 in cohort 2, 2 in cohort 5). Cohort 5 exceeded the maximal tolerated dose. Median follow-up was 2.5 years (range: 0.3-5 years). The 3-year overall and relapse-free survival rates were 86% and 71% respectively; median survival was not reached. CONCLUSIONS: Cisplatin was well tolerated in combination with infusional 5FU and RT, showing promising activity in the adjuvant treatment of gastric cancer. Infusional 5FU 200 mg/m(2) daily for 12 weeks with cisplatin 40 mg/m(2) in weeks 1, 3, 5, and 7 and with concurrent RT 45 Gy in 25 fractions, starting at day 16, is being explored in a phase II study at our institution.
OBJECTIVE: This phase I study aimed to determine the maximal tolerated dose of cisplatin administered every 2 weeks with infusional 5-fluorouracil (5FU) and concurrent radiation therapy (RT) in patients after complete resection of gastric adenocarcinoma. METHODS:Patients with resected stage IB to IV (M0) gastric adenocarcinoma were treated with 12 weeks of infusional 5FU (200 mg/m(2) daily) and with RT (45 Gy in 25 fractions starting on day 16). Cisplatin was administered in escalating doses (0, 20, 30, and 40 mg/m(2)) in weeks 1, 3, 5, and 7. In the final cohort, patients received an additional dose of cisplatin (40 mg/m(2)) in week 9. RESULTS: Among the 34 patients [median age: 56 years (range: 31-77 years)] who were assessable for toxicity, 5 experienced dose-limiting toxicities: 1 sepsis (cohort 1), 1 fatigue (cohort 2), 3 upper gastrointestinal toxicity (1 in cohort 2, 2 in cohort 5). Cohort 5 exceeded the maximal tolerated dose. Median follow-up was 2.5 years (range: 0.3-5 years). The 3-year overall and relapse-free survival rates were 86% and 71% respectively; median survival was not reached. CONCLUSIONS:Cisplatin was well tolerated in combination with infusional 5FU and RT, showing promising activity in the adjuvant treatment of gastric cancer. Infusional 5FU 200 mg/m(2) daily for 12 weeks with cisplatin 40 mg/m(2) in weeks 1, 3, 5, and 7 and with concurrent RT 45 Gy in 25 fractions, starting at day 16, is being explored in a phase II study at our institution.
Entities:
Keywords:
5-fluorouracil; Adjuvant therapy; chemoradiation; cisplatin; gastric cancer; phase i study
Authors: C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: M al-Sarraf; K Martz; A Herskovic; L Leichman; J S Brindle; V K Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: A Webb; D Cunningham; J H Scarffe; P Harper; A Norman; J K Joffe; M Hughes; J Mansi; M Findlay; A Hill; J Oates; M Nicolson; T Hickish; M O'Brien; T Iveson; M Watson; C Underhill; A Wardley; M Meehan Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: Brett G M Hughes; Desmond Yip; Michael Chao; Peter Gibbs; Susan Carroll; David Goldstein; Bryan Burmeister; Christos Karapetis Journal: ANZ J Surg Date: 2004-11 Impact factor: 1.872
Authors: M Al-Sarraf; T F Pajak; R W Byhardt; J J Beitler; M M Salter; J S Cooper Journal: Int J Radiat Oncol Biol Phys Date: 1997-03-01 Impact factor: 7.038
Authors: S H Park; D Y Kim; J S Heo; D H Lim; C K Park; K W Lee; S H Choi; T S Sohn; S Kim; J H Noh; Y I Kim; J O Park; K Kim; W S Kim; C W Jung; Y H Im; M H Lee; K Park; C H Park; W K Kang Journal: Ann Oncol Date: 2003-09 Impact factor: 32.976
Authors: T Leong; M Michael; K Foo; A Thompson; D Lim Joon; L Weih; S Ngan; R Thomas; J Zalcberg Journal: Br J Cancer Date: 2003-10-20 Impact factor: 7.640
Authors: S J MacLellan; H J MacKay; J Ringash; L Jacks; Z Kassam; T Conrad; I Khalili; A Okrainec Journal: Surg Endosc Date: 2012-02-21 Impact factor: 4.584
Authors: Tatiana Conrad; Steve MacLellan; Zahra Kassam; Helen Mackay; Ida Khalili; Jenna Sykes; Tom Purdie; Allan Okrainec; Jolie Ringash Journal: Gastric Cancer Date: 2015-09-11 Impact factor: 7.370